SERB Acquires Idefirix Rights for €115M

SERB Pharmaceuticals has secured exclusive rights across Europe and the MENA region for Hansa Biopharma AB's Idefirix® (imlifidase), a novel desensitization therapy for highly sensitized kidney transplant candidates. The strategic acquisition, valued at €115 million, positions SERB to significantly expand access to this critical treatment for a patient population facing substantial transplantation barriers.

The deal comprises an upfront payment of €110 million to Hansa Biopharma, with an additional €5 million contingent upon European Medicines Agency (EMA) approval of Idefirix®. This transaction underscores SERB's commitment to addressing rare and critical diseases, building upon its established European and MENA commercial infrastructure. Jeremie Urbain, Chairman of SERB Pharmaceuticals, highlighted the company's dedication to improving transplant access for highly sensitized individuals who currently have limited therapeutic options.

Idefirix® targets a significant unmet need within the organ transplant sector. Approximately 10-15% of the 70,000 individuals in Europe awaiting kidney transplants are considered highly sensitized. These patients possess pre-formed IgG antibodies that can trigger rapid rejection of donor organs, often leading to prolonged or indefinite waiting periods. The drug's mechanism involves cleaving IgG antibodies, thereby mitigating the risk of antibody-mediated rejection and facilitating transplantation for these challenging cases.

Under the terms of the agreement, Hansa Biopharma will provide comprehensive support to SERB throughout the regulatory submission and EMA review process, particularly following the initial results of the post-authorization efficacy study (PAES). Once SERB obtains marketing authorization, it will assume responsibility for the ongoing PAES follow-up and a pediatric study, signaling a seamless transition of the program.

The acquisition is subject to standard closing conditions, including foreign direct investment approvals, which are anticipated within 60 days. This move by SERB is particularly noteworthy in a global kidney transplant market projected to grow substantially, driven by increasing rates of end-stage renal disease and advancements in transplant immunology. The ability to successfully desensitize highly sensitized patients represents a key frontier in maximizing organ utilization and improving patient outcomes.

Financial advisory for SERB was provided by Rothschild & Co., with legal counsel from Freshfields. Hansa Biopharma was advised financially by Centerview Partners UK LLP and legally by Morgan Lewis. The successful integration of Idefirix® into SERB's portfolio is expected to enhance its therapeutic offerings in specialized medical fields and potentially set new benchmarks for managing immunological challenges in transplantation.